MX367792B - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. - Google Patents
Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.Info
- Publication number
- MX367792B MX367792B MX2014010258A MX2014010258A MX367792B MX 367792 B MX367792 B MX 367792B MX 2014010258 A MX2014010258 A MX 2014010258A MX 2014010258 A MX2014010258 A MX 2014010258A MX 367792 B MX367792 B MX 367792B
- Authority
- MX
- Mexico
- Prior art keywords
- replicating
- mosquitoes
- attenuated recombinant
- incapable
- equine encephalitis
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 241000255925 Diptera Species 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000003362 replicative effect Effects 0.000 title abstract 2
- 241001502567 Chikungunya virus Species 0.000 abstract 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 abstract 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 1
- 241000710951 Western equine encephalitis virus Species 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 | |
| PCT/US2009/000458 WO2009131604A2 (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX367792B true MX367792B (es) | 2019-09-05 |
Family
ID=41217313
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010258A MX367792B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2019010530A MX378503B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010530A MX378503B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (enExample) |
| EP (2) | EP3085787B1 (enExample) |
| JP (1) | JP5758632B2 (enExample) |
| KR (2) | KR101913790B1 (enExample) |
| CN (1) | CN102083986B (enExample) |
| AU (1) | AU2009238667A1 (enExample) |
| CA (2) | CA2713165C (enExample) |
| CO (1) | CO6290702A2 (enExample) |
| IL (2) | IL207167A (enExample) |
| MX (3) | MX367792B (enExample) |
| MY (1) | MY178870A (enExample) |
| NZ (2) | NZ603790A (enExample) |
| SG (2) | SG187513A1 (enExample) |
| WO (1) | WO2009131604A2 (enExample) |
| ZA (1) | ZA201005943B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2183368T3 (pl) * | 2007-06-21 | 2016-12-30 | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych | |
| WO2009131604A2 (en) | 2008-01-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| BR112015006840A2 (pt) | 2012-09-27 | 2017-11-21 | Res Found Dev | vírus chikungunya atenuado |
| MX361342B (es) | 2013-03-14 | 2018-12-04 | Takeda Vaccines Inc | Composiciones y metodos para formulaciones de alfavirus vivos atenuados. |
| MX2018011839A (es) * | 2016-03-31 | 2019-05-23 | Takeda Vaccines Inc | Constructos de alfavirus vivo atenuado y metodos y usos de los mismos. |
| PH12018502460B1 (en) * | 2016-05-27 | 2023-11-08 | Univ Griffith | Arthrogenic alphavirus vaccine |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| WO2020028749A1 (en) * | 2018-08-03 | 2020-02-06 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Seattle Project Corp. | Modified adenoviruses |
| AU2020417800A1 (en) | 2019-12-31 | 2022-07-14 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| JP5016305B2 (ja) * | 2003-03-20 | 2012-09-05 | アルファヴァックス，インコーポレイテッド | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 |
| US7603447B2 (en) | 2004-07-30 | 2009-10-13 | Research In Motion Limited | Method and system for coordinating device setting between a communications client and its host device |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| WO2009131604A2 (en) * | 2008-01-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
-
2009
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367792B (es) | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. | |
| HK1216618A1 (zh) | 新城疫病毒及其用途 | |
| AU2017240801A8 (en) | Chimeric receptors to FLT3 and methods of use thereof | |
| MX2017004617A (es) | Variantes estabilizadas de alfa amilasa y su uso. | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| MY150613A (en) | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses | |
| MX2012015203A (es) | Composiciones transparentes de limpieza de baja irritacion con ph relativamente bajo. | |
| EP4233843A3 (en) | Antibody compositions | |
| MX2015012107A (es) | Barras limpiadoras que comprenden copolímeros anfifílicos superhidrófilos y métodos de uso de estas. | |
| MX2018011534A (es) | Metodos para transfectar plantas y para reducir eventos de integracion aleatoria. | |
| MX2021011514A (es) | Poliésteres modificados químicamente y proceso para su preparación. | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
| WO2009048633A3 (en) | Chimeric chikungunya virus and uses thereof | |
| NZ631012A (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| MY166879A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| PH12020500144A1 (en) | Method for configuring operating time period for mailbox content and insant messaging content in system | |
| WO2014136065A8 (en) | Production of catalytically active type i sulfatase | |
| MX2019013641A (es) | Antigenos de pertussis acelulares no entrelazados para uso en vacunas de combinacion. | |
| CA3156472A1 (en) | POLYMER COMPOSITION | |
| EP2504029A4 (en) | COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA | |
| WO2019210282A3 (en) | Mycobacterial antigen compositions and methods of use | |
| MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
| MX2019002497A (es) | Peptido con actividad para cicatrizacion de heridas. | |
| MX2019010572A (es) | Composicion que comprende avelumab. | |
| WO2012056387A3 (en) | A dermaceutical gel made using sodium fusidate and a process to make it |